Coexistence of Multiple Myositis-Specific Antibodies in Patients with Idiopathic Inflammatory Myopathies

• Published in: Journal of clinical medicine 2022-11, Vol.11 (23), p.6972
• Main Authors: Huang, Hung-Ling, Lin, Wen-Chih, Tsai, Wei-Lun, Weng, Chia-Tse, Weng, Meng-Yu, Wu, Chun-Hsin, Sun, Yuan-Ting
• Format: Article
• Language: English
• Subjects: Antibodies; Clinical medicine; Enzymes; Hospitals; Inflammatory diseases; Musculoskeletal diseases; Patients; Serology
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11236972

The mutual exclusivity of myositis-specific antibodies (MSAs) has been reported before, but the coexistence of 2 or more MSAs was still found in a few case reports. This study aims to confirm the existence and prevalence of double MSAs in patients with idiopathic inflammatory myopathy (IIM) and to clarify the clinical features of these patients. One hundred fifty-one patients with IIM diagnosed from 1 July 2018 to 31 July 2022, at National Cheng Kung University Hospital, Taiwan, were enrolled and divided into two groups, patients with ≤1 MSA ( = 128, 84.8%) and those with ≥2 MSAs ( = 23, 15.2%) according to the initial serology results. After being re-examined by ANA-IIF assay, 8 out of 23 patients were confirmed to have ≥2 MSAs. The demographic data and clinical features were presented. The prevalence of double-positive MSAs among IIM was 5.3% in this cohort. The coexistence of two MSAs in an IIM patient does exist but is rare. Patients with two MSAs belonging to two distinct IIM subtypes presented clinical features skewed to one subtype instead of "mixed phenotypes". No apparent difference in clinical severity was found between patients with ≥2 MSAs and ≤1 MSA. Longer follow-ups and more studies are required to characterize the patients of IIM with ≥2 MSAs.